Clinical trial
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
NCT01742793 is registered in ClinicalTrials.gov with Yale University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
- Lead sponsor
- Yale University
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 31, 2012
- Completion date
- August 31, 2016
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hodgkin's lymphoma, mature t-cell lymphoma, multiple myeloma